Biotechnology

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

A groundbreaking implantable cell therapy shows consistent, positive results for a debilitating complication of Crohn's disease, paving an expedited path to market.

With its acquisition offer falling short of a majority, Cycle Pharma extends its tender for Applied Therapeutics, leaving the company's fate in the balance.

Industry leaders at the GenScript Global Forum agree: the era of AI experimentation is over. Now, the hard work of scaling and building trust begins.

The deal gives Demeetra sole control of the Super piggyBac platform, aiming to resolve IP hurdles and accelerate non-viral gene therapy development.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

NewcelX sharpens its focus on a Type 1 Diabetes cell therapy, but faces a competitive landscape and significant financial hurdles in its ambitious quest.

A German biotech's novel oral drug for herpes is moving to Phase 2 trials, offering new hope against a widespread and often resistant virus.

ENA Respiratory's INNA-051 nasal spray, a virus-agnostic shield, has begun Phase II trials, offering new hope for high-risk communities.

As Personalis heads to a key investor conference, its groundbreaking cancer tech faces off against questions of revenue volatility and profitability.

Alcami promotes a decade-long leader to COO, a strategic move to harness internal talent and manage its rapid growth in the booming CDMO market.

A new partnership marries AI design with high-throughput lab validation, creating a blueprint to accelerate the creation of new medicines.

A single-injection radiotherapy for canine arthritis is proven safe and effective in a new study, changing how vets and owners manage chronic joint pain.

Enveric Biosciences raises $1.5M to advance its novel psychiatric drugs. Is this small cash infusion enough to propel its promising pipeline forward?

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.

BioBridges and its legacy brands consolidate into Peritia, a new end-to-end platform designed to accelerate product development for resource-strapped teams.

Over 60% of cats and 59% of dogs are overweight, a silent crisis shortening lives. Vets warn against risky shortcuts and urge proactive, guided care.

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.